Policy Developments - The National Health Commission will hold a press conference on November 27, 2025, to discuss the progress and effectiveness of grassroots medical and health services [1] Industry Initiatives - Beijing's Economic and Information Technology Bureau, along with six departments, has introduced measures to accelerate the promotion of artificial intelligence-assisted diagnostic technologies, including financial support of up to 50 million yuan for selected projects [2] Regulatory Approvals - Saikexide has obtained registration for three medical device products, enhancing its product range in the in vitro diagnostic field [3] - Xinhua Pharmaceutical has received a drug registration certificate for a compound local anesthetic cream, with an estimated sales revenue of 615 million yuan in 2024 [4] - Heng Rui Medicine has received approval for clinical trials of its innovative anti-tumor drug HRS-8364, with a cumulative R&D investment of approximately 21.65 million yuan [5] Capital Market Activities - Suzhou High-tech plans to sell a 47% stake in its medical device subsidiary for 604 million yuan [6] - Shanghai DeYin Technology has completed a Pre-A round financing of several million yuan, backed by listed company Songlin Technology [8] Industry News - Novartis China has responded to rumors of dissolving its county-level team, stating it will adjust its operational model while continuing to serve the county medical market [9] - Samsung Medical's subsidiary has been recommended as a candidate for a procurement project with a total expected amount of approximately 107 million yuan [10] Legal Matters - Foreign companies have filed a Section 337 investigation request against specific antibody-drug conjugates, alleging infringement of trade secrets, involving companies from the US, Netherlands, and China [11] Shareholder Actions - Bid Pharma's shareholder plans to reduce their stake by up to 0.16% between December 17, 2025, and March 16, 2026, due to funding needs [12]

厦门松霖科技股份有限公司 2025 年第三次临时股东会 会议资料 证券代码：603992 二〇二五年十二月 1 | | | 厦门松霖科技股份有限公司 2025 年第三次临时股东会通知 一、召开会议的基本情况 （一）股东会类型和届次 2025 年第三次临时股东会 （二）股东会召集人：董事会 （三）投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的 方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 1 日 14 点 30 分 厦门松霖科技股份有限公司 2025 年第三次临时股东会 召开地点：厦门市海沧区阳光西路 298 号 （五）网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自 2025 年 12 月 1 日 至 2025 年 12 月 1 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东会 召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平 台的投票时间为股东会召开当日的 9:15-15:00。 （六）融资融券、转融通、约定购回 ...

| 证券代码：603992 | 证券简称：松霖科技 | 公告编号：2025-084 | | --- | --- | --- | | 转债代码：113651 | 转债简称：松霖转债 | | 厦门松霖科技股份有限公司 关于 2023 年限制性股票激励计划首次授予部分第一个解 除限售期解除限售暨上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股 数为2,778,000股。 本次股票上市流通总数为2,778,000股。 本次股票上市流通日期为2025 年 11 月 24 日。 2025年11月13日，厦门松霖科技股份有限公司（以下简称"公 司"或"松霖科技"）召开第三届董事会第二十七次会议，审议通过 了《关于2023年限制性股票激励计划首次授予部分第一个解除限售 期解除限售条件成就的议案》，现就相关事项说明如下： 一、2023 年限制性股票激励计划批准及实施情况 （一）2023 年限制性股票激励计划已履行的相关程序 1、2023 年 11 月 30 ...

Core Viewpoint - Songlin Technology announced that shareholder Ms. Zhou Lihua plans to reduce her holdings by up to 200,000 shares, representing 0.05% of the company's total share capital [1] Summary by Relevant Sections - **Shareholder Information** - Ms. Zhou Lihua directly holds 2,970,188 shares, accounting for 0.69% of the company's total share capital [1] - The shares were acquired before the company's initial public offering and became tradable after the lifting of restrictions on August 25, 2022 [1] - **Reduction Plan** - Ms. Zhou Lihua intends to reduce her holdings through centralized bidding [1] - The maximum number of shares to be sold is 200,000 [1]

Core Viewpoint - The company has decided to terminate the 2023 restricted stock incentive plan due to changes in the international economic and trade environment, as well as the need for strategic upgrades, which do not align with the current development needs of the company [1] Group 1 - The company will not proceed with the second and third phases of the restricted stock incentive plan, nor the reserved grants [1] - All restricted stocks granted under this incentive plan that have not yet been released from restrictions will be repurchased and canceled [1] - Related documents, including the implementation assessment management measures for the 2023 restricted stock incentive plan, will also be terminated [1]

Core Viewpoint - Songlin Technology (603992.SH) has decided to terminate its 2023 restricted stock incentive plan due to changes in the international economic and trade macro environment, as well as the company's strategic iteration and upgrade, which do not align with the current development needs of the company [1] Group 1 - The company believes that the current restricted stock incentive plan cannot meet the expected incentive goals and effects that align core employee work objectives with the company's development needs [1] - The decision includes the termination of the second and third phases of the incentive plan and the repurchase and cancellation of all restricted stocks that have been granted but not yet released from restrictions [1] - Related documents, including the "Implementation Assessment Management Measures for the 2023 Restricted Stock Incentive Plan of Xiamen Songlin Technology Co., Ltd.", will also be terminated [1]

Core Viewpoint - Songlin Technology (603992.SH) announced that shareholder Zhou Lihua plans to reduce holdings through centralized bidding, with a total reduction not exceeding 200,000 shares, accounting for 0.05% of the company's total share capital [1] Summary by Relevant Sections - Shareholder Action - Zhou Lihua intends to reduce holdings by up to 200,000 shares [1] - This reduction represents 0.05% of the total share capital of Songlin Technology [1]

厦门松霖科技股份有限公司 关于股东减持股份计划公告 证券代码：603992 证券简称：松霖科技 公告编号：2025-083 转债代码：113651 转债简称：松霖转债 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 股东名称 | 周丽华 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | √是 | □否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：不适用 | | | | 持股数量 | 2,970,188股 | | | | 持股比例 | 0.69% | | | 一、减持主体的基本情况 1 股东持股的基本情况 截至本公告披露日，股东周丽华女士直接持有公司 2,970,188 股，占公司总 股本的 0.69%，为公司首次公开发行前取得的股份，于 2022 年 8 月 25 日解 除限售后上市流通。 减持计划的主要内容 周丽华女士计划通过集中竞价方式合计减 ...

1、公司符合《管理办法》《激励计划》规定的实施股权激励 计划的条件，具备实施股权激励计划的主体资格，符合《激励计 划》中对首次授予部分第一个解除限售期可解除限售条件的要求， 未发生《激励计划》中规定的不得解除限售的情形； 2、首次授予部分第一个解除限售期可解除限售的激励对象 不存在《管理办法》规定的不得成为激励对象的情形：（1）最近 12 个月内被证券交易所认定为不适当人选；（2）最近 12 个月内 被中国证监会及其派出机构认定为不适当人选；（3）最近 12 个 月内因重大违法违规行为被中国证监会及其派出机构行政处罚 或者采取市场禁入措施；（4）具有《公司法》规定的不得担任公 司董事、高级管理人员情形的；（5）法律法规规定不得参与上市 公司股权激励的；（6）中国证监会认定的其他情形； 第 1 页 共 2 页 厦门松霖科技股份有限公司提名与薪酬委员会 关于 2023 年限制性股票激励计划首次授予部分 第一个解除限售期可解除限售激励对象名单的核查意见 厦门松霖科技股份有限公司（以下简称"公司"）提名与薪酬 委员会依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》、《上市公司股权激励 ...

第 1 页 共 5 页 于提请股东大会授权董事会办理 2023 年限制性股票激励计划相关事 宜的议案》，公司独立董事发表了同意的独立意见。 证券代码：603992 证券简称：松霖科技 公告编号：2025-078 转债代码：113651 转债简称：松霖转债 厦门松霖科技股份有限公司 关于调整 2023 年限制性股票激励计划回购价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性 承担法律责任。 厦门松霖科技股份有限公司（以下简称"公司"）于 2025 年 11 月 13 日召开第三届董事会第二十七次会议，审议通过了《关于调整 2023 年限制性股票激励计划回购价格的议案》。董事会根据《上市 公司股权激励管理办法》（以下简称《管理办法》）、公司《2023 年限制性股票激励计划》（以下简称《激励计划》或"本激励计划"） 的相关规定和公司 2023 年第四次临时股东大会的授权，对公司 2023 年限制性股票激励计划（以下简称"本次激励计划"）回购价格进 行了调整，现将有关事项说明如下： 一、本次限制性股票激励计划已履行的决策程序和信息披露情 ...